Mr Brian Leedman is a biotechnology entrepreneur having co-founded seven healthcare companies on the ASX. Digital respiratory diagnostics company, ResApp Health Limited, in which he served as the Executive Director of Corporate Affairs was acquired by Pfizer in 2022. Mr Leedman also served as Chairman of Neurotech International Limited, Nutritional Growth Solutions Limited, Neuroscientific Biopharmaceuticals Limited and Ausbiotech (WA). He was a Director of Alcidion Corporation Limited, Oncosil Medical Limited, Respiri Limited and a founder of Imugene Limited. Previously, he spent a decade as the vice president of investor relations at ASX, Nasdaq and Frankfurt listed, pSivida Corporation (renamed Eyepoint Therapeutics) and held senior marketing positions at Westpac Banking Corporation and Ernst & Young. He holds a B.Econs and an MBA from the University of Western Australia.
Brian Leedman returned to Stocks in the Vines and provide an update on the company’s recent milestones, focusing on their AI-powered smartphone technology designed to diagnose autism and ADHD:
Why invest in BlinkLab?
BlinkLab (ASX: BB1) combines proprietary technology, clinical validation studies, and a clear, staged regulatory pathway to commercialisation, addressing an unmet medical need in autism assessment.
Unmet medical need
Given the clear gap in the autism evaluation process, BlinkLab is developing a product that brings objective measurement into clinician-led assessment.
The problem
Autism evaluations remain clinician-led and observation-based, and therefore inherently subjective, leading to variability across clinicians and sites. The lack of objective measures in the evaluation process creates an unmet medical need. That leaves specialists reliant on observation-based assessment alone and contributes to later, less accurate autism identification.
The opportunity
BlinkLab is addressing this unmet medical need by bringing objective, reflex-based measures into clinician-led, observation-based autism assessment through an AI-powered, smartphone-based diagnostic tool that can be used in a comfortable at-home setting. By reducing reliance on observation-based assessment alone, BlinkLab’s approach is designed to help specialists identify autism earlier and more accurately.
🎥 What’s Next for BlinkLab? Brian Leedman on the Next Six Months:
What are the key milestones investors should be watching over the next six months? In this interview from Stocks in the Vines – Investor Access Day 2026, Peter Taylor asks Brian Leedman to share the company’s upcoming catalysts as it advances its AI-powered smartphone diagnostic platform for autism and ADHD:
Brian outlines the milestones ahead, including progress toward U.S. FDA clearance, expansion of BlinkLab’s ADHD program, commercialisation plans and the next phase of the company’s growth strategy.
Following a successful capital raise, BlinkLab is entering a pivotal period with several value-driving milestones on the horizon.
Brian Leedman returned to Stocks in the Vines and provide an update on the company’s recent milestones, focusing on their AI-powered smartphone technology designed to diagnose autism and ADHD:
Why invest in BlinkLab?
BlinkLab (ASX: BB1) combines proprietary technology, clinical validation studies, and a clear, staged regulatory pathway to commercialisation, addressing an unmet medical need in autism assessment.
Unmet medical need
Given the clear gap in the autism evaluation process, BlinkLab is developing a product that brings objective measurement into clinician-led assessment.
The problem
Autism evaluations remain clinician-led and observation-based, and therefore inherently subjective, leading to variability across clinicians and sites. The lack of objective measures in the evaluation process creates an unmet medical need. That leaves specialists reliant on observation-based assessment alone and contributes to later, less accurate autism identification.
The opportunity
BlinkLab is addressing this unmet medical need by bringing objective, reflex-based measures into clinician-led, observation-based autism assessment through an AI-powered, smartphone-based diagnostic tool that can be used in a comfortable at-home setting. By reducing reliance on observation-based assessment alone, BlinkLab’s approach is designed to help specialists identify autism earlier and more accurately.
🎥 What’s Next for BlinkLab? Brian Leedman on the Next Six Months:
What are the key milestones investors should be watching over the next six months? In this interview from Stocks in the Vines – Investor Access Day 2026, Peter Taylor asks Brian Leedman to share the company’s upcoming catalysts as it advances its AI-powered smartphone diagnostic platform for autism and ADHD:
Brian outlines the milestones ahead, including progress toward U.S. FDA clearance, expansion of BlinkLab’s ADHD program, commercialisation plans and the next phase of the company’s growth strategy.
Following a successful capital raise, BlinkLab is entering a pivotal period with several value-driving milestones on the horizon.
